Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Reactions Weekly
Published in: Reactions Weekly 1/2022

01-06-2022 | osteosarcoma | Case report

Nivolumab

Hepatitis: case report

Published in: Reactions Weekly | Issue 1/2022

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
…
Literature
Hamilton C, et al. SEVERE IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HEPATITIS SUCCESSFULLY TREATED WITH BASILIXIMAB. Pediatric Blood and Cancer 69 (Spec. issue 2): S154-S155 (plus poster) abstr. 445, Jun 2022. Available from: URL: http://​doi.​org/​10.​1002/​pbc.​29735 [abstract]
Metadata
Title
Nivolumab
Hepatitis: case report
Publication date
01-06-2022
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-18066-9

Other articles of this Issue 1/2022

Reactions Weekly 1/2022 Go to the issue

Case report

Elasomeran

Case report

Antineoplastics

Case report

Immunosuppressants

Case report

Pembrolizumab

Case report

Dextran

Case report

Mometasone/potassium permanganate